Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura

Transfusion

Volumn 56, Issue 2, 2016, Pages 354-359

  Connell, Nathan T ^a   Cheves, Tracey ^b   Sweeney, Joseph D ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; PLASMAPHERESIS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TURNAROUND TIME; BLOOD; MIDDLE AGED; MORTALITY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VERY ELDERLY;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84958927321     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13359     Document Type: Article

References (15)

1. von Baeyer H., Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 2002; 6: 320-8.
2. Furlan M, Robles R, Galbusera M, et al., von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
3. Bianchi V, Robles R, Alberio L, et al., Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-3.
4. Zheng XL., Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost 2013; 11 Suppl 1: 11-23.
5. Moake JL., Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
6. Franchini M, Mannucci PM., Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura. Blood Transfus 2008; 6: 127-35.
7. Penfold RB, Zhang F., Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr 2013; 13: S38-44.
8. George JN., How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116: 4060-9.
9. Sarode R, Bandarenko N, Brecher ME, et al., Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014; 29: 148-67.
10. Tripodi A, Chantarangkul V, Böhm M, et al., Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 1601-9.
11. Tripodi A, Peyvandi F, Chantarangkul V, et al., Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008; 6: 1534-41.
12. Barrows BD, Teruya J., Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura. Arch Pathol Lab Med 2014; 138: 546-9.
13. Shah N, Rutherford C, Matevosyan K, et al., Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 2013; 163: 514-9.
14. Mancini I, Valsecchi C, Lotta LA, et al., FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thromb Haemost 2014; 112: 297-303.
15. Mackie I, Langley K, Chitolie A, et al., Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost 2013; 109: 488-96.